Xinjiang Zhongtai Chemical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or major omissions.
According to the proposal on the impairment provision for the year 2025 approved by the Company's ninth session of the second Board of Directors, the announcement is as follows:
I. Overview of the Impairment Provision for Assets and Credit
(1) Reasons for the Impairment Provision
In accordance with the "Enterprise Accounting Standards," "Shenzhen Stock Exchange Stock Listing Rules," and other relevant regulations, to accurately reflect the Company's financial status, asset value, and operating results, and based on the principle of prudence, the Company conducted a comprehensive review and impairment testing of accounts receivable, inventory, fixed assets, and other assets. An impairment provision was made for relevant assets showing signs of impairment as of December 31, 2025.
(2) Categories and Amounts of Impairment Provisions
The impairment provisions for the current period mainly involve accounts receivable, other receivables, inventory, and fixed assets. The specific impairment provisions for 2025 are as follows:
| Item | Amount (CNY 10,000) |
|---|---|
| Credit impairment loss | -976.15 |
| - Accounts receivable | -5,341.53 |
| - Other receivables | 4,365.37 |
| Asset impairment loss | 24,057.08 |
| - Inventory impairment | 13,089.29 |
| - Fixed asset impairment | 10,967.79 |
| Total | 23,080.93 |